Your Brain Is Running Low on Its Own Weed, and That’s a Problem
A study highlighted by Futurism last week led with a provocative headline: the older you get, the more weed you should smoke. Predictably, that framing got people talking. But the actual science underneath it points somewhere more interesting than the clickbait suggests, and considerably more important.
The short version: your brain produces its own cannabis-like compounds, that production declines with age, and the consequences of that decline look a lot like the early stages of neurodegeneration. Whether you smoke, eat, or never touch cannabis in your life, the endocannabinoid system is silently running your brain’s maintenance program. And for most people, it’s running short.
What the Research Actually Says
The Futurism piece drew from work out of the Salk Institute focusing on cannabinol (CBN), a compound that forms as THC ages and breaks down. CBN is largely non-psychoactive. What it is, according to Salk researchers, is neuroprotective.
Senior author Pamela Maher, a research professor heading Salk’s Cellular Neurobiology Laboratory, put it plainly: CBN protects neurons from oxidative stress and cell death, two of the major contributors to Alzheimer’s disease. The mechanism involves mitochondrial function. Many neurological disorders, Alzheimer’s and Parkinson’s chief among them, involve neurons dying because their mitochondria stop working properly. CBN appears to block the specific pathway, called oxytosis/ferroptosis, through which this mitochondrial dysfunction kills brain cells.
In the most recent published iteration of this research, appearing in a 2025 study using aging mouse models, CBN improved spatial memory and learning, restored markers of synaptic function, and enhanced mitochondrial health. The effects were more pronounced in female subjects than male, which is a useful data point for a disease that disproportionately affects women.
A separate study published in JAMA Network Open in 2024 found no significant link between middle-aged and older adults who recently began using cannabis medically and cognitive decline or impairment. Carl Hart, a Columbia University psychologist, has argued publicly that the adult brain is considerably more resilient to the downsides of cannabis use than the cultural narrative suggests. His own experimental work found that adults given the opportunity to use cannabis before a math test, with real money on the line for accuracy, showed minimal impact on performance.
None of this is conclusive. The Salk work is still in cell culture and animal model territory. Human clinical trials for CBN as a neuroprotective agent don’t exist yet at meaningful scale. But the directional signal across multiple independent research groups is consistent: cannabinoids interact with the aging brain in ways that are more protective than harmful, and the existing scientific establishment has badly underinvested in understanding that relationship.
The Endocannabinoid System: The System Nobody Taught You About
Most people know their cardiovascular system, their immune system, their nervous system. Ask them about the endocannabinoid system and you’ll get a blank stare. This is a regulatory failure more than a scientific one, because the ECS was only mapped in the early 1990s, and it happened precisely because scientists were trying to figure out why THC does what it does. They found receptors in the brain designed to interact with cannabinoids. And then they asked the obvious question: why would those receptors exist if the body wasn’t producing something similar on its own?
The answer is that it does. The two primary endocannabinoids are anandamide, named from the Sanskrit word for bliss, and 2-arachidonoylglycerol, usually shortened to 2-AG. These molecules bind to cannabinoid receptors, primarily CB1 (concentrated in the brain, governing memory, mood, and pain) and CB2 (distributed through immune tissue and peripheral organs), and regulate an enormous range of functions: sleep, appetite, inflammation, stress response, neuroplasticity, pain modulation, immune balance.
The ECS is, in a real sense, the body’s internal homeostasis manager. When it’s working properly, you handle stress, inflammation heals properly, memory consolidates, and mood stays regulated. When it isn’t, you get disruption across all those systems simultaneously.
The Decline Nobody Is Talking About
Here’s where aging enters the equation in a way that isn’t widely discussed. The endocannabinoid system deteriorates with age, and the deterioration is measurable.
Research published in the International Journal of Molecular Sciences documented that endocannabinoid signaling is markedly decreased in the hippocampus of aged mice, and that genetic deletion of CB1 receptors accelerates the onset of cognitive decline and produces age-related histological changes in the brain. The researchers found the ECS most strongly affected during middle age, not just in late life, which means the slide starts earlier than most people would expect.
A 2026 study published in Scientific Reports found that levels of anandamide and related fatty acid-derived endocannabinoids decline with biological aging, reflecting broader shifts in lipid metabolism and receptor function. CB1 receptor density drops by roughly 50% across a lifespan. The enzyme FAAH, which breaks down anandamide, becomes more active in older brains, meaning the endocannabinoids that do get produced are cleared faster. The net result is a system running at a fraction of its youthful capacity.
Stanford research teams led by neuroscientists Ivan Soltesz and Katrin Andreasson have gone further, identifying a specific pathway through which declining ECS function in aging brains generates prostaglandins, inflammatory molecules linked to cognitive decline. Their work showed it was possible to reverse cognitive decline in aged mice by targeting this pathway — restoring ECS function to a more youthful state in animals that already had established deficits.
Neurologist Ethan Russo, who served as Medical Director for GW Pharmaceuticals during the development of Epidiolex and Sativex, proposed the theory of Clinical Endocannabinoid Deficiency (CED) to describe conditions that may result from insufficient endocannabinoid tone. Many of those conditions, migraines, fibromyalgia, irritable bowel syndrome, disrupted sleep, chronic inflammation, are disproportionately common in older adults. The CED framework suggests this isn’t coincidence.
The Supplement Analogy
I want to be direct about how I think about this, because I think the framing matters.
We accept without much controversy that vitamin D levels decline with age, that supplementing it supports bone density and immune function, and that a large portion of older adults are deficient. We accept that omega-3 fatty acid intake matters for cardiovascular and cognitive health and that most people don’t get enough from diet alone. We accept that hormonal decline with age, testosterone, estrogen, DHEA, has downstream effects on energy, cognition, and physical recovery, and that addressing those deficiencies can meaningfully improve quality of life.
The endocannabinoid system fits the same framework. It produces compounds your brain and body require for homeostatic regulation. Those compounds decline with age. The deficit produces measurable effects on cognition, inflammation, sleep, and pain. And there are ways to address that deficit.
Phytocannabinoids, cannabinoids derived from the cannabis plant, interact with the same receptors your endocannabinoids do. THC binds CB1 and CB2 directly. CBD modulates the system more indirectly, partially by inhibiting FAAH, the enzyme that breaks anandamide down, which means CBD extends the life of the anandamide you’re already producing. CBN, as the Salk research documents, delivers neuroprotective effects through mitochondrial pathways that don’t require direct receptor binding at all.
The reason older cannabis users so commonly report more energy, faster recovery, better sleep, and reduced pain isn’t a placebo effect or a cultural story. It is, at least in part, a straightforward consequence of replenishing a system that had been running deficient. The mechanism is real. The biochemistry is documented.
You Don’t Have to Get High
This is the part of the conversation that gets lost when the discussion focuses entirely on cannabis as an intoxicant. Getting high is one thing the plant does. Delivering phytocannabinoids that interact with your ECS is a different thing, and the two are separable.
A full-spectrum hemp oil contains CBD, CBG, CBN, minor cannabinoids, and terpenes, with THC at or below 0.3%. Zero psychoactivity. The entourage effect, the interaction between multiple cannabinoids and terpenes that produces effects greater than any single compound, still applies. You get ECS support without intoxication.
Raw cannabis takes this further. In its unheated state, the cannabis plant does not contain psychoactive THC. It contains THCA, the acidic precursor form of THC. THCA only converts to THC through decarboxylation, the application of heat. Eat raw cannabis, juice fresh leaves, blend the plant material into a smoothie, and you are consuming THCA, CBDA, and a full complement of cannabinoid acids, terpenes, and flavonoids with no psychoactive effect whatsoever. Research published in the British Journal of Pharmacology found THCA functions as a neuroprotective agent and potent PPARγ agonist. A 2023 study found CBDA and THCA may help protect the brain from Alzheimer’s disease markers and improve memory in animal models.
The raw cannabis smoothie sounds unusual, but it is pharmacologically coherent. You are treating the plant as a functional food delivering compounds your ECS is designed to use. The taste is grassy and requires masking, which is why blending with fruit works. But the underlying logic is the same as eating any other nutrient-dense vegetable for a specific health purpose.
Other Paths to the Same System
Cannabis and hemp are not the only levers available. The ECS responds to a range of inputs, and most of them cost nothing.
Exercise increases anandamide levels measurably. Researchers now believe endocannabinoids, not endorphins, are the primary driver of what athletes call runner’s high. A meditation study published in Frontiers in Psychiatry found that participants in a four-day yoga and meditation retreat showed endocannabinoid increases exceeding 70% across all major ECS markers, with mood improvements sustained a month later. Oxytocin, released through physical touch, social bonding, and sexual activity, stimulates anandamide production directly. Cold exposure increases CB1 receptor density. Omega-3 fatty acids from fish, flaxseed, and chia seeds provide the lipid precursors the ECS uses to synthesize endocannabinoids in the first place. Chronic stress does the opposite, depleting ECS tone, which is part of why stress management practices matter more than most people treat them.
Phytocannabinoids work best in the context of a lifestyle that supports ECS function broadly. Exercise plus a full-spectrum oil is more effective than either alone. The system is responsive to multiple inputs simultaneously, and treating it as such produces better outcomes than any single intervention.
The Reframe
The Futurism headline, the older you get, the more weed you should smoke, is provocative in a way that’s counterproductive to serious engagement with the science. The actual argument is more precise and more important.
As you age, your endocannabinoid system declines. That decline is associated with increased inflammation, cognitive changes, disrupted sleep, altered pain processing, and a higher susceptibility to neurodegenerative conditions. Cannabinoids, both the ones your body produces and the ones the cannabis plant provides, regulate all of those functions. The Salk Institute has documented neuroprotective effects from CBN specifically against the mitochondrial pathway most associated with Alzheimer’s and Parkinson’s. Independent research supports cognitive resilience in older cannabis users.
None of this means lighting up is a medical prescription. It means the ECS is a legitimate target for healthy aging, that cannabis-derived compounds are among the tools available to support it, and that the cultural and legal stigma attached to those compounds has suppressed research that people now need.
Your grandparents were told aspirin was fine and cannabis was dangerous. We now know aspirin causes internal bleeding in chronic high doses. Cannabis, meanwhile, has CB1 receptors in every region of the brain associated with the functions that degrade with age.
The system was always there. We just spent fifty years being told to ignore it.
Sources
Futurism — Research Suggests the Older You Get, the More Weed You Should Smoke (June 21, 2026): https://futurism.com/health-medicine/research-smoke-weed-older
Salk Institute — Active ingredient in cannabis protects aging brain cells: https://www.salk.edu/news-release/active-ingredient-in-cannabis-protects-aging-brain-cells/
Salk Institute — Protecting brain cells with cannabinol (April 17, 2024): https://www.salk.edu/news-release/protecting-brain-cells-with-cannabinol/
PubMed Central — Cannabinol (CBN) alleviates age-related cognitive decline by improving synaptic and mitochondrial health (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12150171/
ScienceDirect — Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors: https://www.sciencedirect.com/science/article/abs/pii/S0891584922000016
JAMA Network Open — Cannabis use and cognitive outcomes in middle-aged and older adults (2024): https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823671
MDPI International Journal of Molecular Sciences — Dynamic Changes in the Endocannabinoid System during the Aging Process (2022): https://www.mdpi.com/1422-0067/23/18/10254
Nature Scientific Reports — Age differences in endocannabinoid tone are ameliorated after recent cannabis use (January 2026): https://www.nature.com/articles/s41598-025-27618-1
Stanford Report — Unraveling the role of endocannabinoid metabolism in brain aging (January 2025): https://news.stanford.edu/stories/2025/01/unraveling-the-role-of-endocannabinoid-metabolism-in-brain-aging
PubMed Central — Inner Engineering Practices and Advanced Meditation Associated with Cannabimimetic Effects with Increased Endocannabinoids (Frontiers in Psychiatry): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293737/
Medical News Today — Can you get high from eating raw weed?: https://www.medicalnewstoday.com/articles/can-you-get-high-from-eating-raw-weed
WorldHealth.net — The Endocannabinoid System: A Key Player in Healthy Aging and Longevity: https://worldhealth.net/news/endocannabinoid-system-health-aging-longevity/
AGING BRAINS FOR CANNABIS, READ ON…
